Clinical Trial: A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855016) titled 'A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma' on Sept. 21.

Brief Summary: This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naive mantle cell lymphoma (MCL).

Study Start Date: Oct. 10

Study Type: INTERVENTIONAL

Condition: Mantle Cell Lymphoma (MCL)

Intervention: DRUG: TT-01488 Tablets

Oral

DRUG: Rituximab

Intravenous Injection (IV)

DRUG: Immunomodulatory Agent

Oral

DRUG: BCL2 Inhibitor

Oral

Recruitment St...